Partnering and collaborations are essential parts of PEPTONIC medical’s business model. We are dependent on our partners for advancing the development of our pipeline products according to our plans and expectations. Hence, we put a lot of emphasis on partnering activities and on managing our partnerships and alliances.
PEPTONIC medical’s most advanced program – Vagitocin® (oxytocin) for the treatment of vaginal atrophy – is in clinical development (Phase 2). We are seeking partners for advancing the program towards registration and commercial launch.
In addition to vaginal atrophy, PEPTONIC medical owns patents relating to a number of medical indications and uses. Please, contact us for more information about these opportunities.
For information about partnering and partnering opportunities, please contact;